Drug Profile
Valtorcitabine
Alternative Names: Epcitabine; L-dC; LDC300; monoval-LdC; NM-147; NV-02C; Torcitabine; val-L-dC; Valtorcitabine dihydrochlorideLatest Information Update: 02 Oct 2007
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals
- Class Antivirals
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 28 Sep 2007 Discontinued - Phase-II for Hepatitis B in USA (PO)
- 18 May 2006 Phase-IIb clinical trials of valtorcitabine + telbivudine for Heptitis B in USA (PO)
- 11 Jul 2005 Novartis has obtained the right to commercialise valtorcitabine in all areas of the world, Idenix has retained the right to co-promote or co-market in the US, UK, France, Germany, Spain and Italy